Merck Tbk

merk

Overview

MERK Overview

PT Merck Tbk is an Indonesia-based vibrant science and technology company. The Company delivers personalized treatments for serious diseases and enable people to achieve their dream of becoming parents. The Company operates through three segments: Biopharma (ethical products), Consumer Health (over-the-counter products) and Others.

5101520ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: MERK

Development
Market Cap.
IDR 1.81Trillion

~$115.48M USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

MERK Valuation Metrics

4,010

IDR

Closing Price on 2024-04-05

Price to Equity

11.31

P/E

At 11.31x P/E TTM, MERK.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 8.9x).

Price to Book

2.44

P/B

At 2.44x P/B TTM, MERK.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 1.3x).

Price to Sales

1.75

P/S

At 1.75x P/S TTM, MERK.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 0.8x).

Valuing Merck Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing Merck Tbk relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow
7.94x
Price/Forward Earnings
-
Enterprise Value/Revenue
1.60x
Enterprise Value/EBITDA
7.34x
PEG Ratio
0.23x

Analyst Ratings

No analyst ratings available yet.

Last closing: IDR4,0102024-04-05
IDR 5,034.12

Considerably Higher Intrinsic Value: Analyst's intrinsic value is of MERK is IDR5,034, which is 27% higher than MERK's last closing price of IDR4,010 (as of 2024-04-05).

Valuation Recap of MERK stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 11.31x is above the ID market average of 8.22x and is trading at a premium to peers in the Pharmaceuticals & Health Care Research sector (8.87x).
Max 3
High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 2.44x is above the peers average of 1.29x in the Pharmaceuticals & Health Care Research sector.
Max 3
Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 1.75x is above the peers average of 0.80x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of MERK's valuation relative to its current sales and future earnings growth.
Max 2
Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. MERK's P/CF ratio of 7.94x is considered healthy by analysts.
Max 2
Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. MERK's EV/R ratio of 1.60x is considered fairly underpriced by the market The average EV/R ratio for the Pharmaceuticals & Health Care Research sector is 1.40x.
Max 3
Medium
Considerably Higher Intrinsic Value: Analyst's intrinsic value is of MERK is IDR 5,034.12, which is 27% higher than MERK's last closing price of IDR 4,010.00.●●●
Max 3

Peers

MERK Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk68.46T27.18T 30.31T 2.96T 23.123.31
MIKAPT Mitra Keluarga Karyasehat Tbk.39.22T7.11T 4.13T 0.95T 41.297.01
SILOPT Siloam International Hospitals Tbk.32.40T10.75T 10.83T 1.11T 29.294.28
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.62T 2.35T -0.05T -433.0911.10
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk20.25T3.75T 3.61T 0.97T 20.865.94
HEALPT Medikaloka Hermina Tbk.19.03T8.52T 5.54T 0.48T 39.485.15
PRAYPT Famon Awal Bros Sedaya Tbk9.42T4.42T 1.70T 0.18T 53.643.42
TSPCTempo Scan Pacific Tbk9.09T11.31T 12.93T 1.41T 6.431.18
SOHOPT Soho Global Health Tbk6.24T4.67T 7.91T 0.34T 18.422.45
KAEFKimia Farma Tbk.5.04T8.99T 10.19T -0.17T -30.26
Competitiveness Recap of MERK stock
WeightNotesScore
High
At a market cap of IDR 1,814.49 billion, MERK.JK ranks 10 in Market Cap out of 10 companies in the Healthcare sector.
Max 2
High
At a PE of 11.31, MERK.JK ranks 8 out of 10 companies in the Healthcare sector for P/E value. The average PE is -18.93 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (53.64) in the Healthcare sector.
Max 2
Medium
At a PE of 11.31, MERK.JK is trading at a higher PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 8.87). false
Max 2
Medium
At a revenue of IDR 1.04 trillion, MERK.JK ranks 10 in Revenue out of 10 companies in the Healthcare sector.
Max 2
Medium
At a profit of IDR 0.16 trillion, MERK.JK ranks 9 in Profit out of 10 companies in the Healthcare sector.
Max 2

Future

Future Growth of MERK

Growth Forecasts

No data available

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are shrinking at a projected rate of -1.18% against the IDX average of +12.0%.

Pharmaceuticals & Health Care Research sector overview
No data is available for MERK at the moment.
Future growth prospect of MERK
WeightNotesScore
High
MERK's projected growth rate of -1.18% is below the ID market average of 11.98%.●●●
Max 3
High
The Pharmaceuticals & Health Care Research sub-sector is projected to grow revenue by 11.14% in 2024. This number is higher than the previous year 2023's growth rate of 2.48%. This bodes well for MERK's revenue growth prospects in the next 2 years. ●●
Max 3
Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to increase earnings by 2.56% in 2024. This number is higher than the previous year 2023's EPS growth of -8.71%. false
Max 3
Medium
MERK and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2024. Specifically, earnings are projected to increase by 16.30% in 2024 while revenue growth is projected to increase by 17.10%. These macroeconomic trends will likely be a tailwind for MERK's earnings growth prospects in the next 2 years. ●●
Max 3
Loading...
Loading...

Management

Executive Management

President Director

Evie Yulin15.2 years
Bambang Nurcahyo
Director
Arryo Aritrixso Wachjuwidajat
Director
NamePositionShares%
No data is available for MERK at the moment.
Expressed in millions IDR, unless otherwise stated

Ownership

MERK Ownership

Others
11.99%
Insiders
86.65%
Institutions
1.36%
NameNumber of SharesOwnership (%)Value
Merck Holding Gmbh331,483,000741,329.25B
Emedia Export Company Mbh56,711,92013227.41B
Public (Scripless)55,487,08012222.50B
Public (Scrip)4,318,000117.32B
No data is available for MERK at the moment.